



61ST Annual World Congress • ICA 2019
A World of Opportunities in Vascular Medicine

International College of Angiology

Jointly Sponsored by

OhioHealth Continuing Medical Education, Columbus, Ohio

October 10-12, 2019

Abstract Deadline: 15 May 2019

Oral Presentation Poster Presentation (*electronic*) Young Investigator Award Competition*

**(Past recipients of the Young Investigator Award Competition are ineligible)*

ONLY ONE ABSTRACT PER PRESENTER WILL BE CONSIDERED FOR PRESENTATION

YOUR ABSTRACT MUST BE SUBMITTED VIA EMAIL or THROUGH OUR ONLINE ABSTRACT SUBMISSION ON THE COLLEGE'S WEBSITE.
Abstracts **MUST** be structured as follows: (1) Abstract Title (2) Author(s) (3) Academic Affiliations of Author(s) (4) Background (5) Objectives (6) Methods (7) Results (8) Conclusions. **PDF FILES ARE UNACCEPTABLE.**

ABSTRACT TITLE

Author(s): Please indicate the presenting author with an asterisk (*)

Degrees and Academic Affiliations of Author(s) (Please list ALL)

Presenting Author's E-mail, Full Mailing Address, and Fax (Please list full mailing address and email)

ABSTRACT (350 word limit)

IN SUBMITTING YOUR ABSTRACT, THE FOLLOWING INFORMATION IS COMPULSATORY:

- What professional practice gap does this abstract address?
- How will this abstract influence change in competence, performance or patient outcomes?
- A list of references (page 5) that support the key teaching points **MUST** be submitted with your abstract.

Abstracts not complying with the above information and POLICY and DISCLOSURE STATEMENTS on the reverse side WILL NOT be considered!

Abstract submission:

International College of Angiology, Scientific Committee

Denise M. Rossignol, Executive Director

161 Morin Drive, Jay, Vermont 05859-9238

TEL: +802.988.4065; FAX: +802.988.4066; E-MAIL: denise.m.rossignol@intlcollegeofangiology.org or denisemrossignol@cs.com

PLEASE NOTE THE FOLLOWING INSTRUCTIONS FOR THE PREPARATION OF ABSTRACTS
ONLY ONE (1) ABSTRACT PER PRESENTER WILL BE CONSIDERED BY THE SCIENTIFIC COMMITTEE-NO EXCEPTIONS
ABSTRACT GUIDELINES

General Page Set-up: Submit your original abstract via e-mail or via the ICA's Website (preferred). Substances should be named by their international non-proprietary (generic) name. All abstract submissions or the manuscript thereof must not have been accepted for presentation and/or publication at another scientific meeting or journal. **DO NOT SEND YOUR ABSTRACT IN PDF FORMAT.**

Author(s): Insert all authors' full name, middle initial and surname, degrees, department, and address in this section. Indicate the corresponding author with full mailing address and e-mail address. **The presenter MUST submit a current, abbreviated CV with your abstract submission.**

- Abstracts must be written in English and should be structured in such a way as to include: Background, objectives, methods, results and conclusions.
- All abbreviations must be defined before being used as an abbreviation in the text.
- The content of the abstract is solely the responsibility of the author. The original abstract is reprinted exactly as provided. It is therefore essential that the abstracted is correctly typed. Avoid errors, corrections and misspellings.
- Abstracts should contain no more than 350 words of text in the recommended font: Times New Roman, size 12 pt. Do NOT use a smaller font size.
- If including a table in the abstract, please limit the number of words in the body of the abstract to 225. If including a diagram, please ensure that the abstract text together with the diagram do not exceed one page. **ALL DIAGRAMS OR PICTURES MUST BE IN JPEG FORMAT.**
- Use single spacing.
- Presentations must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality. If the CME educational material or content includes trade names, where available trade names from several companies should be used, not just trade names from a single company.
- All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.
- All scientific research referred to, reported, or used in a CME activity in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection and analysis.

Policy Statement

The International College of Angiology requires that audiences at the ICA's educational programs be informed of a presenter's (moderators, speakers, faculty, authors and contributors) academic and professional affiliations, as well as other commercial relationships relevant to the content of the material that is presented.

The policy allows the listener/attendee to be fully informed in evaluating the information being presented. The situations may include, but are not limited to 1) stock options or bond holdings in a for-profit corporation or self-directed pension plan, 2) research grants, 3) employment (full or part time), 4) ownership or partnership, 5) consulting fees or other remuneration received by the presenter or his/her immediate family, including support that may be provided to attend the educational meeting, 6) non-remunerative positions of influence such as officer, board member, trustee, or public spokesperson. The disclosure will be shown as an indication (by two **) for those presenters who have stated that a relationship(s) exists relevant to the topic(s) being discussed.

Indicate any author(s) who has a possible conflict of interest (see policy statement above) by two (2) ** next to that author(s) name in the heading of the abstract.

DISCLOSURE

This program must insure balance, independence, objectivity, and scientific rigor in all educational activities. Faculty and planners participating in such activities must disclose any significant financial interests or other relationships. Any potential conflicts of interest will be revealed and resolved in the course syllabus.

FINANCIAL RELATIONSHIPS, CONFLICTS OF INTEREST & OFF-LABEL DISCLOSURE POLICIES

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria for promotional speakers' bureau, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Individuals need to disclose relationships with a commercial interest if both (a) the relationship is financial and occurred within the past 12 months and (b) the individual has the opportunity to affect the content of CME about the products or services of that commercial interest.

Conflict of Interest: A potential conflict of interest exists when there is involvement between the speaker/presenter with any for-profit commercial form or organization (FPC). This includes, but is not limited to, one or more of the following: consultant, scientific advisory committee member; or lecturer for a FPC from which income is derived; officer, board member, trustee, owner or employee of an FPC; stock or bond holdings in an FPC (investments entirely managed by a third party such as mutual funds and pension plans are excluded); stock options held in an FPC.

Off-Label Disclosure (Including Generic Trade Names and Reporting Scientific Research): Presentations must give a balanced view of options. Faculty use of generic names will contribute to this impartiality. Presentations supported by any commercial entity reporting the results of scientific research must conform to the generally accepted standards of experimental design, data collection, and analysis. When an unlabeled use of a commercial product, or an investigational use not yet approved for any purpose is being discussed during an educational activity, it is required that the speaker disclose that the product is not labeled for the use under discussion or that the product is still investigational.